Viking therapeutics aktie

Cookie Einstellungen.

Up to The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK treatment to be safe and well tolerated with the majority of treatment emergent adverse events TEAEs being categorized as mild or moderate. Patients receiving weekly doses of VK demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to Patients receiving VK also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the week treatment period.

Viking therapeutics aktie

.

Viking Therapeutics emerges as a strong weight loss drug player - or takeover target. Kurs: 2.

.

All of the shares of common stock to be sold in the proposed offering are to be sold by Viking. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Viking currently intends to use the net proceeds from the proposed offering for continued development of its VK, VK and VK programs and for general research and development, working capital and general corporate purposes. The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3 File No. The securities may be offered only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.

Viking therapeutics aktie

Conference Call Scheduled for Wednesday, February 7 at p. Eastern Time. The company will host a conference call to discuss financial results and general corporate updates beginning at p. Eastern Time on Wednesday , February 7, To participate on the conference call, please dial from the U. In addition, following the completion of the call, a telephone replay will be accessible until February 14, by dialing from the U. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.

Audi charleston wv

Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Watchlist Watchlist anlegen. Mean baseline body weight kg 3. Notwendig Details einblenden. Nachrichten Nachrichten Nachrichten auf FN. Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the week treatment period. This press release contains forward-looking statements regarding Viking Therapeutics, Inc. Dividende je Aktie: -. The company is also evaluating an oral formulation of VK in a Phase 1 trial. The year to date growth is at VK demonstrated encouraging safety and tolerability following 13 weeks of once-weekly dosing. Insiderhandel: 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 9. Patients receiving weekly doses of VK demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to

Key events shows relevant news articles on days with large price movements. Madrigal Pharmaceuticals Inc.

Umsatz: -. Today, I present an intriguing short trade idea for VKTX stock, capitalizing on a market structure shift to the downside. Land: USA. Sektor: Gesundheit. Watchlist Watchlist anlegen. Marktkapitalisierung: Mio. Marktkapitalisierung: PR Newswire Ad hoc-Mitteilungen. This press release contains forward-looking statements regarding Viking Therapeutics, Inc. Extremely big news. Erweiterte Suche. The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK demonstrating statistically significant reductions in body weight compared with placebo. In addition, following the completion of the call, a telephone replay will be accessible until March 5, , by dialing from the U. Viking Therapeutics emerges as a strong weight loss drug player - or takeover target.